Strategic Initiative: Jammu Facility Upgradation
Ind-Swift Laboratories Limited is upgrading its manufacturing facility located at Jammu, J&K to EU-GMP/PICS standards to meet increased demand for its products in export markets.
Facility Details:
- Current status: WHO-GMP and ISO 9001:12008 compliant
- Built in 2008 with 14,700 sq meters built-up area
- Installed capacity: Oral Solid Dosage (OSD) and Ointments manufacturing
- Currently serves domestic market and soft regulated markets
- Also caters to leading domestic third-party manufacturing
Upgradation Plan:
- Total planned investment: ₹45 crores (excluding R&D investment for facility upgradation, product development, and production registrations)
- Expected completion: Early 2028
- Post-upgradation capability: Will cater to European and other regulated markets worldwide
Expected Financial Impact:
- Additional revenue target: ₹100 crores annually
- Revenue timeline: From FY 2029-30 onwards
- Strategic role: Will supplement both CDMO (Contract Development and Manufacturing Organization) and own branding business
Q1 FY27 Financial Performance
The company recently declared its Q1 financial results for FY27 showing significant improvement:
Operating Performance:
- Operating Income: ₹186.08 crore, up 21.16% YoY from ₹153.58 crore in Q1 FY26
- Operating EBITDA: ₹33.32 crore, improved 2.85 times YoY from ₹8.66 crore
- Operating EBITDA Margin: 17.91%, expanded by 1,258 basis points YoY from 5.33%
Profitability:
- PAT (excluding exceptional items): ₹24.68 crore, increased 2.04 times YoY from ₹8.12 crore
- PAT Margin: 13.26%, improved by 827 basis points YoY from 4.99%